UGT1A1 and chronic myelogenous leukemia, BCR-ABL1 positive: The study by Abumiya et al. [79], includes 34 Japanese patients with imatinib-resistant or newly diagnosed CML and demonstrates that the ratio of nilotinib concentration(C0) to total bilirubin levels in CML patients with UGT1A1 *6/6* or *6/*28 genotypes was higher than those with UGT1A1 *1/*1, *1/*6, *1/*28, or *27/28* genotypes.